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Mammalian fetuin-A and fetuin-B are abundant serum proteins with pleiotropic
functions. Fetuin-B is a highly selective and potent inhibitor of metallo-
peptidases (MPs) of the astacin family, which includes ovastacin in mammals.
By inhibiting ovastacin, fetuin-B is essential for female fertility. The crystal
structure of fetuin-B was determined unbound and in complex with archetypal
astacin, and it was found that the inhibitor has tandem cystatin-type modules
(CY1 and CY2). They are connected by an exposed linker with a rigid, disulfide-
linked ‘CPDCP-trunk’, and are followed by a C-terminal region (CTR) with
little regular secondary structure. The CPDCP-trunk and a hairpin of CY2 form
a bipartite wedge, which slots into the active-site cleft of the MP. These elements
occupy the nonprimed and primed sides of the cleft, respectively, but spare the
specificity pocket so that the inhibitor is not cleaved. The aspartate in the trunk
blocks the catalytic zinc of astacin, while the CY2 hairpin binds through a
QWVXGP motif. The CY1 module assists in structural integrity and the CTR is
not involved in inhibition, as verified by in vitro studies using a cohort of mutants
and variants. Overall, the inhibition conforms to a novel ‘raised-elephant-trunk’
mechanism for MPs, which is reminiscent of single-domain cystatins that target
cysteine peptidases. Over 200 sequences from vertebrates have been annotated
as fetuin-B, underpinning its ubiquity and physiological relevance; accordingly,
sequences with conserved CPDCP- and QWVXGP-derived motifs have been
found from mammals to cartilaginous fishes. Thus, the raised-elephant-trunk
mechanism is likely to be generally valid for the inhibition of astacins by
orthologs of fetuin-B.
1. Introduction
Fetuin was discovered in 1944 as the most abundant globulin
in fetal calf serum (Pedersen, 1944). Today, fetuins constitute a
broad group of liver-derived plasma and matrix proteins (Lee,
2009). These include fetuin-A, also known as 2-Heremans–
Schmid glycoprotein, and fetuin-B, which was discovered as a
paralog of fetuin-A in 1999 (Olivier et al., 2000; Denecke et al.,
2003). Fetuins belong to the cystatin family of proteins (Turk
& Bode, 1991), which matches family I25 of the MEROPS
database (https://www.ebi.ac.uk/merops). This family is derived
from the archetypal reversible inhibitor specific for cysteine
peptidases, the monomeric 116-residue chicken egg-white
cystatin (ovocystatin; Bode et al., 1988; Stubbs et al., 1990).
Among the cystatins, fetuins belong to subfamily I25C, also
referred to as type-3 cystatins, which groups glycosylated
proteins with two or three cystatin-like repeats (Rawlings &
Barrett, 1990; Lee, 2009). Fetuins consist of tandem cystatin
domains (hereafter referred to as CY1 and CY2) followed by
a C-terminal region (hereafter referred to as CTR). Another
member of this subfamily is histidine-rich glycoprotein, a two-
repeat plasma protein from vertebrates that is involved in
the vascular, coagulation and immune systems and is not a
peptidase inhibitor (Turk & Bode, 1991). Yet other members
are the kininogens, which are the precursors of the kinin
hormones and are initiators of the surface-activated blood-
coagulation cascade. They comprise three cystatin modules,
the last two of which inhibit cysteine peptidases (Salvesen et
al., 1986). Finally, the subfamily also includes endogenous
inhibitors of snake-venom metallopeptidases (MPs) from the
ADAM/adamalysin family (Gomis-Ru¨th, 2013). These inhi-
bitors contain two cystatin modules and operate through an
unknown mechanism.
Fetuin-A serum levels are high throughout life and are even
higher during fetal development; fetuin-B is less abundant
than fetuin-A (Floehr et al., 2016, 2017). Despite their
common phylogenetic origin and close chromosomal location
within all studied vertebrate genomes, fetuin-A and fetuin-B
are chemically different and have separate biological func-
tions. An important role in mineralized matrix metabolism has
been demonstrated for fetuin-A, among several other moon-
lighting functions (Jahnen-Dechent et al., 2011), while fetuin-B
is essential for fertilization (Dietzel et al., 2013; Sto¨cker et al.,
2014). It blocks the proteolytic activity of ovastacin, a member
of the astacin family (Gomis-Ru¨th, Trillo-Muyo et al., 2012)
within the metzincin clan of MPs (Gomis-Ru¨th, 2009; Cerda`-
Costa & Gomis-Ru¨th, 2014). Ovastacin mediates the hard-
ening of the zona pellucida (ZP), a glycoprotein matrix
surrounding the oocyte, by cleaving the ZP component ZP2
after gamete fusion (Burkart et al., 2012) and thus preventing
further sperm from penetrating the oocyte. By blocking
ovastacin, fetuin-B counteracts premature ZP hardening
before fertilization and therefore maintains female fertility by
keeping the ZP penetrable to sperm (Ko¨rschgen et al., 2017).
Detailed biochemical analysis revealed that mammalian
fetuin-B inhibits its physiological target ovastacin at picomolar
concentrations and most other astacins, for example crayfish
astacin, zebrafish nephrosin and human meprins  and , at
nanomolar concentrations (Karmilin et al., 2019). As no other
peptidase type was inhibited, fetuin-B is considered to be an
endogenous and specific inhibitor of non-BMP-1-like astacins
(Karmilin et al., 2019). It complements the broad-spectrum
pan-peptidase inhibitor 2-macroglobulin (Goulas et al., 2017)
and Xenopus laevis Sizzled/Ogon, which blocks BMP-1-like
astacins (Lee et al., 2006). In addition, a carp ortholog of fetuin
strongly inhibited carp nephrosin, an endogenous astacin
family member (Tsai et al., 2004). Finally, unlike fetuin-B and
despite conflicting reports (Yamamoto & Sinohara, 1993;
Yoshida et al., 1996; Hedrich et al., 2010), fetuin-A is not a
peptidase inhibitor (Lee, 2009; Dietzel et al., 2013; Karmilin
et al., 2019; Galembeck & Cann, 1974): depending on the
analyzed peptidase, the apparent inhibitory activity of
fetuin-A was owing to contaminating fetuin-B or to chromo-
genic substrate competition by fetuin-A.
Currently, more than 200 sequences, exclusively from
vertebrates, have been annotated as fetuin-B in the UniProt
database. This supports a ubiquity and physiological relevance
of this protein that is probably associated with the selective
and pleiotropic inhibition of a family of MPs. To understand
this function at the molecular level and to guide the rational
design of small-molecule regulators, we solved the structure of
mouse fetuin-B both unbound and in complex with the
archetypal MP astacin, which is a valid model for the
physiological target ovastacin. We verified the findings using
inhibitory assays of recombinant protein variants, and further
discuss the implications of this novel inhibition mechanism.
2. Materials and methods
2.1. Protein production and purification
Crayfish astacin was purified from the digestive fluid of the
European freshwater crayfish Astacus astacus L. as described
by Gomis-Ru¨th et al. (1993). Recombinant mouse pro-
ovastacin was obtained as reported by Dietzel et al. (2013) and
was proteolytically activated with plasmin (Karmilin et al.,
2019). Human meprin  was obtained as described by Becker
et al. (2003) and was activated with trypsin (Fridrich et al.,
2016). Mouse fetuin-A and mouse fetuin-B, as well as the
mouse fetuin-B loop-swap variant mFBH1-swap, in which the
sequence Q199WVSGP204 is replaced by Q78EDMGP82, were
hexahistidine-tagged at the C-terminus, cloned in pFASTBac1
vector and expressed in baculovirus-transduced High Five
cells as described for meprin (Becker et al., 2003; Becker-Pauly
et al., 2007). Bovine and human fetuin-B orthologs, as well as
the CY2 (residues K147–F265; mouse fetuin-B residue numbers
are shown as superscripts; see UniProt Q9QXC1) and CTR
(residues F266–P388) domains of mouse fetuin-B and point
mutants (P155A, D156A, P155A+D156A, C154S+C157S and
C39S+C374S) of mouse fetuin-B, were expressed in ExpiCHO-S
cells (ThermoFisher Scientific, Waltham, USA) according to
the manufacturer’s specifications (Karmilin et al., 2019). For
the generation of point mutants of mouse fetuin-B, the original
pcDNATM3.4 TOPO_mouseFetuB construct (Karmilin et al.,
2019) was used as a template for site-directed mutagenesis. All
variants were generated by the QuikChange Lightning Multi
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, USA) using the standard protocol and specific primers.
Following mutagenesis, parental DNA was digested by DpnI.
Afterwards, XL10-Gold ultracompetent cells were trans-
formed with the resulting PCR products according to the
manufacturer’s instructions. The gene sequences were
confirmed by DNA sequencing (Eurofins Genomics, Ebers-
berg, Germany). The chimeric mutant mFBABA comprised the
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CY1 (residues A19–P136; mouse fetuin-A residue numbers
are shown in italics, see UniProt P29699) and CTR (residues
P254–I345) domains of mouse fetuin-A plus an intercalated
mouse fetuin-B CY2 domain (residues V145–Q269) and was
obtained from adenovirus-infected COS-7 cells (Karmilin et
al., 2019). All proteins carry a cleavable C-terminal hexa-
histidine tag and were purified by nickel–nitrilotriacetic acid
(Ni2+–NTA) affinity chromatography as described previously
(Dietzel et al. 2013; Karmilin et al. 2019). Finally, cyclized
peptides including the sequences CPDC (full sequence Ac-
VSKRKTHTTCPDCPSPIDL) and CPRC (full sequence Ac-
DSAEDVRKLCPRCPLLTPFN) were purchased from JPT
Peptide Technologies GmbH, Berlin, Germany.
Mouse fetuin-B was also produced in HEK293S cells, which
synthesize proteins carrying endoglycosidase H-sensitive
Man5GlcNAc2 N-glycans (Reeves et al., 2002). For this, a
cDNA encoding full-length mouse fetuin-B (GenScript) was
cloned in frame with the 30 hexahistidine tag-encoding
sequence of pHLsec2, a mammalian expression vector derived
from pHLsec (Aricescu et al., 2006). The resulting construct
was used for transient transfections using 25 kDa branched
PEI (Sigma–Aldrich; Aricescu et al., 2006). The secreted
fetuin-B was purified by Ni2+–NTA chromatography, degly-
cosylated with endoglycosidase H and purified by size-exclu-
sion chromatography essentially as described by Bokhove et
al. (2016), except that the deglycosylation step was carried out
overnight at 4C. Finally, the protein was concentrated to 7.5–
30 mg ml1 in 150 mM sodium chloride, 20 mM sodium
HEPES pH 7.8.
2.2. Crystallization and diffraction data collection
Crystallization assays of the astacin–fetuin-B complex were
performed using the sitting-drop vapor-diffusion method.
Reservoir solutions were prepared by a Tecan robot and
100 nl crystallization drops were dispensed onto 96  2-well
MRC plates (Innovadyne) at the joint IBMB/IRB Automated
Crystallography Platform at Barcelona Science Park using a
Cartesian MicroSys 4000 XL robot (Genomic Solutions) or a
Phoenix nanodrop robot (Art Robbins). Plates were kept in
Bruker steady-temperature crystal farms at 4 or 20C. Crystals
were obtained by incubating the mouse inhibitor with a sixfold
molar excess of the crayfish peptidase. The best crystals were
obtained at 20C in 0.1 ml:0.1 ml drops with protein solution at
a concentration of 6 mg ml1 with 200 mM sodium chloride,
10 mM Tris–HCl pH 7.8 as the buffer and 0.05 M ammonium
sulfate, 20%(w/v) polyethylene glycol 2000, 0.1M sodium
acetate pH 4.6 as the reservoir solution. Crystals were cryo-
protected by rapid passage through drops containing increasing
concentrations of glycerol [up to 10%(v/v)]. It is noteworthy
that properly diffracting crystals appeared after 4–5 days and
rapidly lost diffracting power after a further 1–2 weeks. SDS–
PAGE and N-terminal Edman degradation of washed and
dissolved complex crystals revealed that fetuin-B was cleaved
at positions S296–S297 within the CTR, which did not alter its
inhibitory properties (data not shown).
Crystals of intact unbound mouse fetuin-B produced in
HEK293S cells were grown using a Mosquito robot (TTP
Labtech) by sitting-drop vapor diffusion at room temperature
against a mother liquor consisting of 100 mM sodium acetate,
25%(w/v) PEG 4000, 8%(v/v) isopropanol.
Diffraction data for the astacin–fetuin-B complex crystals
were collected at 100 K from liquid-nitrogen flash-cryocooled
crystals (Oxford Cryosystems 700 Series Cryostream) using a
PILATUS 6M detector (Dectris) on the XALOC beamline
(Juanhuix et al., 2014) of the ALBA synchrotron, Cerdanyola,
Catalonia, Spain. Diffraction data were processed with XDS
(Kabsch, 2010a) and XSCALE (Kabsch, 2010b), and were
transformed using XDSCONV to a format suitable for the
CCP4 suite of programs (Winn et al., 2011). The crystals
belonged to space group P212121, contained two peptidase–
inhibitor complexes per asymmetric unit (molecules A/B and
C/D, respectively) and diffracted to 3.1 A˚ resolution.
Diffraction data for the free fetuin-B crystals were collected
at 100 K from liquid-nitrogen flash-cryocooled crystals using a
PILATUS 6M-F detector (Dectris) on beamline ID29 (de
Sanctis et al., 2012) at the European Synchrotron Radiation
Facility (ESRF), Grenoble, France. Three 360 wedges
collected from different positions of a single crystal at 7 keV
(1.7712 A˚) were first integrated and scaled with XDS and then
merged with XSCALE, resulting in a 31-fold redundant data
set. The crystals belonged to space group P412121, contained
one inhibitor molecule per asymmetric unit and diffracted to
2.3 A˚ resolution (see Table 1 for data-processing statistics).
2.3. Structure solution and refinement
The structure of the astacin–fetuin-B complex was solved
by maximum-likelihood-scored molecular replacement using
Phaser (McCoy et al., 2007) with the coordinates of the protein
part of unbound astacin (PDB entry 1ast; Bode et al., 1992;
Gomis-Ru¨th et al., 1993) as a search model. These calculations
were followed by automated density modification and model
building with the AutoBuild protocol of the PHENIX suite
(Terwilliger et al., 2008), which included twofold averaging.
The resulting Fourier map initiated 12 rounds of manual
model building with Coot (Emsley et al., 2010), which alter-
nated with crystallographic refinement with PHENIX
(Afonine et al., 2012) and BUSTER/TNT (Smart et al., 2012)
with the inclusion of translation/libration/screw-rotation
refinement and noncrystallographic symmetry restraints. The
final refined model was comprised of residues A1–H202 and
A1–L200 [mature astacin residue numbers are shown in
subscript, as in Gomis-Ru¨th et al. (1993) and Guevara et al.
(2010); add 49 for residue numbers in the full-length sequence;
see UniProt P07584] from astacin molecules A and C,
respectively, plus a zinc cation each, residues R29–P388 (except
for T218–Q227, L246–L251 and P273–A302) plus S501–A502 from the
C-terminal purification tag from molecule B and Q28–P388 plus
S501 (except for T218–H228, H248–L251, S268–A302, D314–P326 and
P354–G355) from molecule D. One N-acetyl-d-glucosamine
(NAG) moiety was attached to N40 and N139 of molecule B,
and one and two NAGmoieties were linked to N40 and N139 of
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molecule D, respectively. Three glycerols plus 46 solvent
molecules completed the model. Some regions of molecule D
were only poorly defined in the final Fourier maps and were
modeled based on molecule B to preserve the overall chain
continuity, as this led to lower free R-factor values. The
satisfactory quality of the final model was assessed with the
wwPDBValidation Service (https://www.wwpdb.org/validation;
Berman et al., 2003).
The structure of isolated fetuin-B was independently solved
by sulfur SAD using the CRANK2 (Pannu et al., 2011)
experimental phasing pipeline of CCP4 Cloud’s jsCoFE
(Krissinel et al., 2018). Using an initial high-resolution cutoff
of 4.5 A˚, this procedure located a substructure that included
12 sites corresponding to five disulfide bonds and three
methionine residues (mean phasing figures of merit of 0.1084
before density modification and 0.4363 after density modifi-
cation with Fourier recycling) and produced an initial model
consisting of 285 amino acids (Rwork = 30.9%, Rfree = 33.8%).
This model was expanded usingAutoBuild within PHENIX. It
was then manually rebuilt with Coot and refined against the
first wedge of diffraction data with PHENIX. The final model
included residues L31–P388 (except for the segments T218–H228,
S244–V255, A270–T295 and E316–S325), one NAG attached to N40
and N139, one acetate and 85 solvent molecules. Structure
validation was performed with MolProbity (Williams et al.,
2018), Privateer (Agirre et al., 2015) and pdb-care (Lu¨tteke &
Lieth, 2004). Data-collection, refinement and validation
statistics are reported in Table 1.
2.4. Inhibition assays in vitro
The inhibitory capacities of fetuin variants towards mouse
ovastacin, human meprin  and crayfish astacin were deter-
mined in vitro by means of a fluorogenic enzyme-activity assay
monitored using a Varioskan Flash 3001 spectral plate reader
equipped with the Skanit 2.4.3.RE software (Thermo Scien-
tific, Dreieich, Germany). Enzyme concentrations for astacin
and meprin  were determined from the absorbance at 280 nm
("astacin = 42 800 M
1 cm1, "meprin  = 106 520M
1 cm1) and
for ovastacin via the IC50 calculation of wild-type murine
fetuin-B. Assays were performed in triplicate at 37C in a
100 ml final volume, with 150 mM sodium chloride, 50 mM
Tris–HCl pH 7.4, 0.01% Brij 35 as the buffer. Enzyme-activity
measurements were started by the addition of 20–30 mM
Ac-RE(Edans)DRNleVGDDPYK(Dabcyl)-NH2 (Biosyntan
GmbH, Berlin, Germany) for ovastacin and meprin  or 70–
80 mM Dansyl-PKRAPWV-OH (PANATecs GmbH, Heil-
bronn, Germany) for astacin dissolved in dimethyl sulfoxide
(final concentration 0.4%). Initial velocities were recorded for
at least 600 s (100 times for 100 ms at intervals of 15 s).
Thereafter, 1.5 ml proteinase K (at 20 mg ml1; Sigma–
Aldrich, Taufkirchen, Germany) or 1 ml astacin (at 200 mM)
were added to reach complete substrate turnover, which was
monitored and subsequently calculated using the formula v =
[S]  m/F, where [S] is the substrate concentration, m is the
(F/t) slope of initial linear substrate turnover and F is the
maximal fluorescence intensity corresponding to complete
turnover. Kinetic parameters of inhibition (Ki) were deter-
mined using Morrison’s equation (Morrison, 1969).
2.5. Bioinformatics
A computational homology model of human fetuin-A was
calculated using the automodel routine of the Modeller v.9.20
suite (Fiser & Sˇali, 2003). The coordinates of mouse fetuin-B
and a curated structure-based sequence alignment of the two
proteins were used for these calculations, and the disulfides
were fixed according to Kellermann et al. (1989). The resulting
model was subjected to visual inspection with Coot to remove
cis-peptide bonds and gross Ramachandran outliers, and was
regularized with the phenix.geometry_minimization protocol
of PHENIX with restraints to the starting model. The final
model was assessed for the correct assignment of secondary-
structure elements by comparison with an independent
comparative model that was automatically generated using
research papers
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Table 1
Crystallographic data.
Values in parentheses are for the outermost resolution shell.
Data set Astacin–fetuin-B Fetuin-B
Space group P212121 P41212
a, b, c (A˚) 83.4, 85.8, 168.7 67.7, 67.7, 197.8
Wavelength (A˚) 0.9792 1.7712
No. of measurements 264256 384912
No. of unique reflections 22647 19993




Completeness (%) 100.0 (100.0) 93.6 (63.0)
Rmerge 0.153 (1.499) 0.109 (1.626)
Rmeas 0.160 (1.567) 0.112 (1.782)
CC1/2 0.998 (0.771) 0.999 (0.521)
Average intensity 14.1 (2.0) 20.3 (1.4)
B factor (Wilson) (A˚2) 78.8 54.2
Avererage multiplicity 11.7 (11.6) 19.3 (6.0)
No. of reflections used in refinement 21981 19989
No. of reflections in test set 643 1000
R factor/free R factor 0.216/0.270 0.224/0.254
Correlation coefficient, Fobs  Fcalc 0.931 0.931
Correlation coefficient, test set 0.882 0.939
No. of protein residues 1127 299
No. of atoms 7899 2344
No. of solvent molecules 46 85
No. of covalent ligands 5 NAG† 2 NAG†
No. of noncovalent ligands 2 Zn2+, 3 glycerol 1 acetate
R.m.s.d. from target values
Bonds (A˚) 0.010 0.002
Angles () 1.14 0.59
Average B factors (A˚2)
Overall 101.2 67.1
Molecule A 79.2 67.7
Molecule B 109.0 —
Molecule C 89.6 —
Molecule D 117.1 —
All-atom contacts and geometry analysis
Residues in favored regions 908 [91.6%] 280 [96.7%]
Outliers 7 0
All residues 991 290
Outlying rotamers 56 [6.4%] 5 [1.8%]
Outlying bonds 0 0
Outlying angles 0 0
Outlying chirality 0 0
Outlying planarity 0 0
All-atom clashscore 4.8 3.2
† N-acetyl-d-glucosamine.
the multiple-template threading program RaptorX (http://
raptorx.uchicago.edu/StructurePrediction/predict; Ka¨llberg et
al., 2012). The quality of the final model is reflected by the
following statistics according to PHENIX: r.m.s.d.s from target
values for bonds, angles, chirality and planarity of 0.002 A˚,
0.57, 0.04 and 0.01, respectively, an all-atom clashscore of
9.7, 1.4% rotamer outliers and no cis-peptide bonds, and 12%
and 88% of residues in allowed and favored Ramachandran
regions, with 0% outliers. The coordinates are available from
the last corresponding author upon request.
Sequences were aligned with MUSCLE (Edgar, 2004) as
implemented in SeaView (Gouy et al., 2010). The alignment
was refined based on the structures of mouse fetuin-B overlaid
with stefin-B (PDB entry 1stf; Stubbs et al., 1990), cystatin-C
(PDB entry 3gax; Kolodziejczyk et al., 2010) and the afore-
mentioned model of human fetuin-A using UCSF Chimera
(Pettersen et al., 2004). Structural figures were prepared with
UCSF Chimera. Secondary-structure predictions were made
with JPred4 (Drozdetskiy et al., 2015). Structural super-
impositions were performed with SSM (Krissinel & Henrick,
2004) within Coot. Protein interfaces were analyzed with PISA
(Krissinel & Henrick, 2007; http://www.ebi.ac.uk/pdbe/pisa).
The area of the complex interface was taken as half of the sum
of the buried surface areas of the molecules. Sequence-
similarity searches were performed with the PSI-BLAST
protocol at NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi) or
the BLAST protocol at UniProt (https://www.uniprot.org/
blast) using default parameters. Sequence identities were
calculated using SIM with default parameters (https://
web.expasy.org/sim/). The final coordinates of the crayfish
astacin–mouse fetuin-B complex and free fetuin-B are avail-
able from the PDB at http://www.rcsb.org (PDB entries 6ht9
and 6hpv, respectively).
3. Results and discussion
3.1. Crystallization of mouse fetuin-B
Several groups have unsuccessfully tried to crystallize
fetuins since their discovery (Pedersen, 1947) and ‘a number
of obvious and potentially serious problems that may forestall
attempts to crystallize fetuin’ were identified (Dziegielewska
& Brown, 1995). Eventually, we obtained crystals of recom-
binant mouse fetuin-B from insect cells by incubation with an
excess of the readily crystallizable MP astacin from crayfish
(33% sequence identity with ovastacin; Gomis-Ru¨th, Trillo-
Muyo et al., 2012) as we failed to obtain sufficiently large
amounts of ovastacin for structural studies. Astacin cleaved
the inhibitor at S296–S297 within the CTR without affecting its
inhibitory properties (data not shown). The resulting astacin–
fetuin-B complex structure was solved by maximum-like-
lihood-scored molecular replacement, followed by density
modification and noncrystallographic symmetry averaging,
and was refined to 3.1 A˚ resolution (Table 1). Once the
complex structure had been solved, we managed to obtain
crystals of intact mouse fetuin-B from HEK293S cells, and the
structure was independently solved by native sulfur phasing
and refined to 2.3 A˚ resolution (Table 1). Examination of the
crystal packing of the protein expressed in mammalian cells
explains why it crystallized in its unbound form, whereas the
material produced in insect cells did not: endoglycosidase H
processing of the high-mannose N-glycans of the HEK293S-
derived protein (a step performed during purification) left a
single N-acetylglucosamine moiety attached to N40 that stacks
against W200 of a symmetry-related molecule (Supplementary
Fig. S1). This introduces a crucial crystal-packing contact that
would most likely be hindered by the presence of additional
sugar residues attached to the core N-acetylglucosamine, such
as those normally found in proteins expressed in insect cells.
3.2. Structure of fetuin-B
The structure of fetuin-B (residues R29–P388) in its astacin
complex includes the domains and segments CY1 (R29–S146),
linker (LNK; K147–P158) and CY2 (S159–E267, except for the
loops T218–Q227 and L246–L251), and S268–V272 plus P303–P388
from the CTR (S268–P388). The N-terminal 118-residue CY1
domain exhibits the cystatin fold and consists of a twisted and
curled five-stranded antiparallel -sheet (strands 1–5) with
simple up-and-down connectivity. An -helix (1) is inserted
between 1 and 2 through short linkers and nestles
perpendicularly to the strands in the concave face of the sheet
[Figs. 1(a) and 1(b)]. Strand pairs 2/3 and 4/5 are
connected by short loops and are arranged as hairpins I and II,
respectively. In contrast, 3 and 4 are connected by a long
21-residue loop (L34), which was found in several confor-
mations in ovocystatin (Engh et al., 1993) and is involved in
the inhibition of legumain (Dall et al., 2015). This ‘legumain-
binding loop’ is internally cross-linked by the disulfide C96–
C107 (‘type-A disulfide’ according to Kellermann et al., 1989).
A second disulfide staples 4 and 5 together, roughly at half
the strand length (C120–C140; type-B disulfide). A fifth cysteine
(C39) in L11 is bound to the CTR through a disulfide (see
below), and two N-glycans are attached to N40 and N139,
respectively. The C-terminal strand of CY1 (5) contains a
bulge and leads to the 12-residue LNK, which consists of a
short -helix (2) and the segment C154PDCP158 arranged in a
tight 1,4-turn of type I, hereafter referred to as the ‘CPDCP-
trunk’ [Fig. 1(c)]. Owing to the prolines and the cysteines,
which are disulfide-linked (C154–C157), this structure forms a
rigid 14-atom ring that protrudes from the molecular surface
[Fig. 1(b)]. In the absence of structural information, this
disulfide had been previously termed type-C and included
within the CY2 domain in fetuins and within the CY2 and CY3
domains in kininogen (Kellermann et al., 1989; Lee, 2009).
The LNK is followed by the 109-residue CY2 domain, which
likewise adopts the cystatin fold and is topologically equiva-
lent to the CY1 domain. It interacts through the convex face of
its -sheet with L12 and the legumain-binding loop from
the CY1 domain [Fig. 1(b)]. Interestingly, the latter loop
encompasses the segment L92ETDCHVLSRKA103, which has
been identified as a characteristic signature of fetuins (Olivier
et al., 2000) according to the PROSITE database (motif
PDOC00966). This supports the hypothesis that the legumain-
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binding loop of the CY1 domain may play a similar adhesive
role at the CY1/CY2 interface in other fetuins. CY1 and CY2
can be superimposed for 78 residues with an r.m.s.d. of 1.6 A˚
despite just 17% sequence identity, and the respective sheet
research papers
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Figure 1
Structure of fetuin-B. (a) Topology scheme of mouse fetuin-B depicting strands as arrows (labeled 1–13) and helices as rods (1–3), each with their
delimiting residues. Domain CY1 is in orange, the linker (LNK) is in red, CY2 is in turquoise and the CTR is in purple. N-glycans are marked with blue
lollipops and labeled. Disulfides are pinpointed as pale green lines and labeled:1 , C39–C374;2 , C96–C107;3 , C120–C140;4 , C154–C157;5 , C217–C224;6 ,
C237–C263. Missing segments are shown as dotted lines, and hairpins I and II of each cystatin domain are further labeled. (b) Ribbon-type plot of mouse
fetuin-B, with each domain colored as in (a). N-glycans are labeled with an encircled ‘A’ (N40) and ‘B’ (N139); P155 and N156 from the CPDCP-trunk are
labeled and their side chains are shown. The N- and the C-termini of the protein are labeled and residues from the purification tag are shown in pink. (c)
The CPDCP-trunk featuring a rigid 14-atom ring (C atoms in gray). (d) Superposition of CY1 (orange), CY2 (cyan) and ovocystatin (purple; PDB entry
1cew; Bode et al., 1988) as C plots. The respective type-A and type B-disulfides are shown in red and labeled, as are the legumain-binding loops in the
three structures, hairpins I and II, and the N- and C-termini. (e) Superposition of the C traces of mouse fetuin-B: unbound (CY1 in yellow, LNK in
green, CY2 in dark blue and CTR in pink) and in complex with astacin [domain colors as in (b)]. The inset shows a close-up showing the CPDCP-trunk,
hairpin I and hairpin II in cross-eyed stereo. The observed differences may be authentic or may be the result of crystal contacts.
strands (6–10 in CY2) and -helices (3 in CY2) coincide
[Fig. 1(d)].
Akin to CY1 strands 4 and 5, a type-B disulfide (C237–
C263) staples 9 and 10 together in the CY2 domain. The
largest difference between the domains is found in the
legumain-binding loop (L89 in CY2), which spans 18 resi-
dues and is partially disordered in the CY2 domain, so that the
corresponding type-A disulfide (C217–C224) is not resolved in
the final Fourier map. Moreover, CY2 is not glycosylated,
L78 (hairpin I) is two residues shorter than in CY1 and
L910 (hairpin II) is partially disordered at its tip, as is
L89. Overall, the CY1 and CY2 domains are topologically
equivalent to ovocystatin, except for the legumain-binding
loop [Fig. 1(d); Bode et al., 1988]: 83 and 97 aligned ovo-
cystatin residues can be superposed with r.m.s.d. values of 2.1
and 2.0 A˚ onto CY2 and CY1 residues, respectively, despite
low sequence-identity values (20% and 16%, respectively).
After the C-terminal strand of CY2 (10), the polypeptide
chain of fetuin-B enters the CTR, which is generally irregu-
larly folded, disordered between P273 and A302, and cleaved at
S296–S297. After P303, the chain runs parallel to strand 5 of
CY1 as strand 11, thus providing a first anchor to CY1 for the
downstream part of the domain. The remaining 78 residues of
the CTR could be traced but are flexible: they lack regular
secondary structure and run irregularly along the convex
surface of the CY1 -sheet. Only two short -strands (12 and
13), which coincide with secondary-structure predictions for
the CTR, interact with each other in an antiparallel manner.
Towards the C-terminus of the domain, C374 is disulfide-linked
to C39, in this way providing a second anchor between the
CTR and CY1. It is noteworthy that the tripeptide C374PG376
is conserved within fetuins, kininogens and histidine-rich
glycoproteins (Olivier et al., 2000). This suggests a similar link
between CY1 and CTR in other fetuins, as experimentally
proven for human fetuin-A and human kininogen (Keller-
mann et al., 1989).
The structure of unbound intact mouse fetuin-B is defined
for residues L31–P388 (except for the segments T218–H228, S244–
V255, A270–T295 and E316–S325), and its superposition on the
structure from the astacin complex reveals no significant
conformational rearrangement [Fig. 1(e)]. The respective
cores comprising CY1+LNK+CY2 are undefined for both the
tip of hairpin II and L89 of CY2, and they superpose with
an r.m.s.d. of 1.7 A˚. CY1 and CY2 are just rotated by 10
with respect to each other when going from the unbound to
the complexed structure. The only functionally relevant
differences in the cores are found at the tips of hairpins I and
II of CY2 [inset in Fig. 1(e)], which however are very likely to
result from crystal contacts in the unbound structure. Hairpin I
is in a noncompetent conformation for binding, and becomes
folded out towards the CPDCP-trunk upon complex forma-
tion. In addition, despite being disordered in both structures,
hairpin II shows some extra ordered residues in the complex
structure, possibly owing to fixing interactions with the target
MP (see below). Although the CTR of unbound fetuin-B is
intact and that of the complexed form is cleaved (see above),
they show similar overall chain traces (except for S348–K357,
D314–E328 and the C-terminal tail after N381), as revealed by an
r.m.s.d. of 1.3 A˚ upon superposition.
3.3. Structure-based mechanism of the inhibition of astacin
by fetuin-B
Astacin is a 202-residue MP (A1–H202). It consists of an
upper subdomain (USD; A1–G99) and a lower subdomain
(LSD; F100–H202) separated by an extended, deep, narrow
active-site cleft (Bode et al., 1992; Gomis-Ru¨th et al., 1993;
Guevara et al., 2010). The USD contains a twisted five-
stranded -sheet, the fourth strand of which shapes the upper
rim of the cleft and runs antiparallel to the other strands and
to substrates bound in the cleft. The USD further contains an
active-site helix. This helix includes two of the catalytic zinc
ligands and the general base/acid for catalysis (H92, H96 and
E93, respectively) embedded in a long zinc-binding consensus
sequence (H92EXXHXXGXXH102), which is a hallmark of
the astacins (Gomis-Ru¨th, Trillo-Muyo et al., 2012) and other
MPs of the metzincin clan (Bode et al., 1993; Gomis-Ru¨th,
2009; Cerda`-Costa & Gomis-Ru¨th, 2014). After G99, the chain
enters the LSD, which contains little repetitive secondary
structure, most notably a kinked C-terminal helix at the end of
the chain. Two further zinc ligands come from the LSD (H102
and Y149), as well as another structural hallmark of astacins
and other metzincins, the Met-turn (Tallant et al., 2010), which
contains a conserved methionine (M147). The C-terminus of
the protein resides on the molecular surface and two disulfides
(C42–C198 and C64–C84) contribute to the overall stability and
rigidity of the molecule.
Mouse fetuin-B potently inhibits its physiological target
ovastacin, human meprin  and archetypal crayfish astacin in
vitro (see Section 3.4 and Karmilin et al., 2019). To account for
this inhibition, the LNK and CY2 form a bipartite wedge,
which slots into the active-site cleft of the target [Figs. 2(a),
2(b) and 2(c)]. In contrast, CY1 makes only a minor contri-
bution to binding and the CTR does not participate at all.
Upon inhibitor binding, the LSD of astacin undergoes a slight
clamshell motion of maximally 2.5 A˚ (at the C atom of
Q118), which closes the active-site cleft as in the complex with
an inhibitor mimicking a reaction intermediate (PDB entry
1qji; Grams et al., 1996). The astacin–fetuin-B complex inter-
face buries an area of 1059 A˚2 and yields a theoretical gain of
solvation energy on complex formation of 10.8 kcal mol1.
The interface involves 33 residues of fetuin-B and 38 of
astacin, which collectively establish ten hydrogen bonds, two
ionic interactions and 20 hydrophobic interactions (see
Table 2). Astacin segments participating in the interaction
include S62–V68 from the upper-rim strand and a preceding
bulge above the primed side of the cleft, Q76 from the fifth
strand, G83–C84 from the loop connecting the fifth sheet strand
to the active-site helix, plus the disulfide C64–C84, the zinc-
binding site and Y101, D121–D129, F154–W158 and Y177 from the
LSD [Fig. 2(c)]. Fetuin-B segments involved include M111–
Y113 from the legumain-binding loop of CY1, K147–S159 from
the LNK and CY2 strand 6, N198–Y206 from CY2 hairpin I
and, to a lesser extent, S245 plus Q253–V255 from CY2 hairpin
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II, the tip of which is disordered [see above
and Figs. 2(a) and 2(c)].
The main interaction is performed by the
rigid CPDCP-trunk of the LNK, which
blocks the nonprimed side of the cleft and
binds the catalytic zinc through the side
chain of D156 in a bidentate manner, thus
occupying the position of a scissile carbonyl
during catalysis. The D156 carboxylate is also
at binding distance from the zinc-binding
atom Y149 O
 and, notably, the carboxylate
of the general base/acid E93, so that either
carboxylate could be protonated. P155
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Figure 2
The astacin–fetuin-B complex. (a) Cross-eyed
stereo cartoon displaying fetuin-B [colors as in
Fig. 1(b)] inserted into the active-site cleft of astacin
(tan ribbon). The MP is shown after a horizontal
90 rotation downwards from the traditional
standard orientation of MPs (Gomis-Ru¨th, Botelho
et al., 2012), so the cleft runs from left (nonprimed
subsites) to right (primed subsites). The catalytic
zinc is shown as a magenta sphere and its astacin
ligands as stick models, as are P155 and D156 from
fetuin-B. (b) Detail of the final (2mFobs  DFcalc)-
type Fourier map at 3.1 A˚ resolution contoured at
1 above the threshold, depicting the zinc-binding
site of astacin (carbons in tan, zinc ion as a magenta
sphere) and the CPDCP-trunk of fetuin B (carbons
in pink). (c) Close-up view of (a) after a horizontal
35 rotation, displaying selected residues partici-
pating in the interaction between fetuin-B (C
ribbon in plum; from left to right, segments S146–
D162, M111–E114, N197–Y206 and T241–S245; carbons in
pink and residue numbers according to UniProt
Q9QXC1 in blue) and astacin (C ribbon in tan,
carbons in orange, catalytic zinc as a magenta sphere
and residue numbers in black italics according to
UniProt P07584). The C154–C157 disulfide from the
CPDCP-trunk of fetuin-B is shown with green
sulfurs. (d) Scheme of the proposed ‘raised
elephant-trunk model’; the view mirrors that in (a)
and (b). The CPDCP-trunk (1 ) would be the raised
trunk (in red) and hairpin I (2 ) and II (3 ) the two
front and back limbs (in turquoise), respectively
(see top-left inset). The trunk contacts the catalytic
zinc ion (magenta sphere) of astacin (in brown) by
residues nestling into cleft subsites S4, S3, S2, S2
0 and
S3
0 , as shown by purple arrows. Dashed lines
represent distantly connected segments or disor-
dered loops. Hydrogen bonds between main-chain
atoms, between side-chain and main-chain atoms,
and between side-chain atoms are shown as gray,
red and blue dashed lines, respectively. The electro-
static interaction between the catalytic zinc and D156
is in light blue. The disulfide connecting the
CPDCP-trunk is shown as a green solid line. (e)
Superposition of the experimental structure of
mouse fetuin-B (white carbons and black labels)
and the comparative model of human fetuin-A
(cyan carbons and blue labels with regular residue
numbers in italics) depicting the regions of the
CPDCP warhead and the tips of hairpins I and II of
each structure. The view results from (c) after a 90
rotation in the plane. The catalytic zinc ion of
astacin is further shown as a magenta sphere for
reference.
nestles into cleft subsite S2 [active-site cleft subsites are shown
in bold; for nomenclature, see Schechter & Berger (1967) and
Gomis-Ru¨th, Botelho et al. (2012)], C154 into S3 and T
153 into
S4. The cysteine sulfurs of the trunk make hydrophobic
interactions with the ring of W65. In addition, residues M
111–
Y113 from the legumain-binding loop of CY1 play a scaffolding
role for the CPDCP-trunk and further establish mixed
hydrophobic and hydrophilic interactions with S62, W65, Y67
and Q76 of astacin [see Table 2 and Figs. 2(c) and 2(d)].
Next in importance to complex formation is CY2 hairpin I,
which blocks the primed side of the cleft. The Q199 side chain
both positions the CPDCP-trunk through a hydrogen bond to
D156 O and binds the main chain of the astacin bulge at S62 O.
The downstream residue W200 makes a hydrophobic inter-
action through one face of its side chain with F154 and M124;
through the other it is kept in place by the side chain of P204
upstream in the hairpin. The V201 side chain occupies S2
0 and
interacts hydrophobically with the sulfurs of the disulfide C64–
C84, while S
202 enters S3
0 [Figs. 2(c) and 2(d)]. Owing to its
missing side chain, the downstream residue G203 is essential to
prevent a clash with W158 of astacin. Moreover, Y
206 estab-
lishes a hydrogen bond to D121. Overall, these interactions are
key for complex formation and comprise a motif for the tip of
CY2 hairpin I (Q199WVSGP204), which is conserved as
QWVXGP among mammalian orthologs (see below, Table 3
and Supplementary Figs. S2 and S3). Finally, weak interactions
are provided by the defined residues of CY2 hairpin II. In
particular, S245 and Q253–V255 are close to Y177 and Q157–V160
of astacin.
Overall, the CPDCP-trunk and CY2 hairpin I both bind in
the direction of a substrate and cover the nonprimed and
primed sides of the active-site cleft from S4 to S3
0. This matches
the preference of the enzyme for elongated substrates (Grams
et al., 1996) and explains the high inhibitory potency of
fetuin-B. However, subsites S1 and S1
0 are spared by the inhi-
bitor, which is noteworthy as S1
0 is the main specificity pocket
of astacins and most MPs (Gomis-Ru¨th, Botelho et al., 2012;
Gomis-Ru¨th, Trillo-Muyo et al., 2012). This enables fetuin-B to
potently inhibit astacin, meprin  and ovastacin (see Section
3.4), despite their differences in substrate specificity (Gomis-
Ru¨th, Trillo-Muyo et al., 2012), and strongly supports astacin–
fetuin-B as a valid model for other complexes with members
of the astacin family of MPs. The free S1
0 pocket may also
explain why the zinc ligand Y149, which undergoes a ‘tyrosine-
switch’ motion upon substrate or inhibitor binding (Grams et
al., 1996; Gomis-Ru¨th, Trillo-Muyo et al., 2012), is found in the
conformation present in unbound astacin structures and the
proenzyme, which likewise evince empty S1
0 pockets (Gomis-
Ru¨th et al., 1993; Guevara et al., 2010). Thus, the bipartite
blockage of the cleft prevents cleavage of the inhibitor, as
occurs for example in standard-mechanism inhibitors of MPs,
which typically run entirely along the cleft (Arolas et al., 2011).
In addition, this mode of inhibition also explains why fetuin-B
does not inhibit BMP-1 and its tolloid(-like) relatives
(Karmilin et al., 2019): these proteins have astacin residue W65,
which is located within the upper-rim strand above the cleft,
replaced by the tripeptide CCG, with the two vicinal cysteines
connected by a cis-peptide bond and a disulfide bond. This
creates a highly strained bulge above the zinc site (see PDB
entry 3edh; Mac Sweeney et al., 2008), which prevents the
fetuin-B CPDCP-trunk from entering the active site. More-
over, the mechanism also explains why CY1 is not inhibitory:
despite its overall structural similarity (see Section 3.2), CY1
lacks an upstream CPDCP-trunk and its hairpin I is two
residues longer at its tip [Fig. 1(d)]. This impairs the func-
tionality of the QWVXGP motif (H76YQEDMGS83 in CY1)
and would cause collision with the primed side of the astacin
cleft. Finally, CY1 hairpin II is seven residues shorter than in
CY2, so that even the minor contribution to inhibition by this
structural element is missing. To sum up, the CPDCP-trunk
and CY2 hairpin I are the major determinants of inhibition,
while CY1 and CTR merely play a scaffolding role.
As to structurally similar inhibitors, human latexin likewise
consists of tandem cystatin-like domains connected by a
helical linker (PDB entry 2bo9; Pallare`s et al., 2005). Latexin is
also very specific to a particular MP family, here the A/B-type
funnelins, which are also known as M14 metallocarboxy-
peptidases (Gomis-Ru¨th, 2008). Like fetuin-B, it inhibits its
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Table 2
Interactions at the astacin–fetuin-B interface.
The first residue/atom belongs to fetuin-B and the second to astacin. The
overall resolution of the structure is 3.1 A˚, the estimated overall average
coordinate error is 0.42 A˚ based on the Luzzati plot, and the dispersion
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targets through the C-terminal cystatin
domain. However, in latexin the two
cystatin domains are packed against
each other through the helices, which
are surrounded by the curved -sheets
arranged in a compact open barrel. In
addition, latexin inhibition is not
exerted by segments that are topologi-
cally reminiscent of the CPDCP-trunk
plus hairpins I and II, but rather
through loops from the opposite edge of
the sheet, equivalent to L63, L37
and L89 of fetuin-B CY2. In
summary, despite the similarity in the
building blocks, the overall structure
and the working mechanism of fetuin-B
are novel for MPs.
3.4. Experimental validation of the
structure-derived mechanism
To verify the abovementioned
mechanism, we tested the inhibition of
several constructs and mutants of
human, mouse and bovine fetuin-B
against crayfish astacin, human meprin
 and mouse ovastacin [Fig. 3(a)], which
add to previous studies (Karmilin et al.,
2019). We also determined the constants
of inhibition (Ki) of selected constructs
and mutants of mouse fetuin-B to
provide quantitative data [Figs. 3(b) and
3(c)].
The three full-length wild-type ortho-
logs completely inhibited all enzymes
[Fig. 3(a)], in accordance with previous
studies (Karmilin et al., 2019). Wild-type
mouse fetuin-B inhibited astacin,
meprin  and ovastacin with similar Ki
values of 100, 81 and 46 pM, respec-
tively [Fig. 3(c)]. In contrast, the Ki
values of a chimera of mouse fetuin-B,
in which CY1 and CTR were replaced
by the homonymous domains of non-
inhibitory mouse fetuin-A (mutant
mFBABA), was decreased by more than
three (astacin) and four (meprin  and ovastacin) orders of
magnitude, respectively [Figs. 3(b) and 3(c)]. The mutants
mFBBAA and mFBBAA could not be produced, which under-
pins the requirement for a complementary CY1–CTR inter-
face for the proper folding of fetuin-B.
A cyclic peptide including a sequence CPDC, which mimics
the isolated CPDCP-trunk between CY1 and CY2, did not
inhibit either enzyme and was indistinguishable from a variant
with an arginine replacing the aspartate [Fig. 3(a)]. Taken
together with the lack of inhibition of isolated domain CY2
[Fig. 3(a)], this indicates that these modules are only functional
within the context of a multi-domain fetuin. Domain CTR
alone did not show inhibition either [Fig. 3(a)], which is
consistent with recombinant carp fetuin truncated after CY2
inhibiting meprin / and carp nephrosin with similar potency
as the functional full-length protein purified from fish blood
(Hedrich et al., 2010). Together, these data point to a negli-
gible role of the CTR in inhibition. Consistently, no reduction
of activity was observed when the cysteines of disulfide C39–
C374 were replaced by serines [Fig. 3(a)], which indicates that
the minimal functional structure does not require the over-
arching clamp between CY1 and CTR.
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Table 3
Potential fetuin-B orthologs in vertebrates.
All sequences contain the intact CPDCP-trunk motif. UP, UniProt; GB, GenBank. Sequence identity with
human fetuin-B was determined only for mammalian sequences, as they share the same overall protein








Human (Homo sapiens) UP Q9UGM5 100 QWVVGP
Western lowland gorilla (Gorilla gorilla) UP G3QMB1 98 QWVVGP
Chimpanzee (Pan troglodytes) UPA0A2J8M5X2 97 QWVVGP
Sumatran orangutan (Pongo abelii) UPA0A2J8WHT1 97 QWVVGP
Fruit bat (Pteropus vampyrus) GB XP_011380247 75 QWVFGP
African elephant (Loxodonta africana) UP G3SVW6 70 QWVVGP
Dog (Canis lupus familiaris) UP E2R9B6 69 QWVYGP
Sperm whale (Physeter catodon) GB XP_007116341 69 QWVFGP
Naked mole rat (Heterocephalus glaber) UP G5BT88 67 QWVVGP
European hedgehog (Erinaceus europaeus) GB XP_007519827 66 QWVFGP
Bovine (Bos taurus) UP Q58D62 66 QWVFGP
Horse (Equus caballus) UP F6RRV1 63 QWVVGP
Mouse (Mus musculus) UP Q9QXC1 63 QWVSGP
Rat (Rattus norvegicus) UP Q9QX79 61 QWVVGP
Pig (Sus scrofa) UP F1SFI6 60 QWVFGP
Koala (Phascolarctus cinereus) GB XP_020844617 50 QWVFGP
Opossum (Monodelphis domestica) GB XP_001373317 47 QWVVGP
Birds
Mallard (Anas platyrhynchos) UP U3IFE7 QMVIGP
Zebra finch (Taeniopygia guttata) UP H0ZJK5 QWVIGP
Rock dove (Columba livia) UP F1NHT5 QWVIGP
Collared flycatcher (Ficedula albicollis) UP U3K0K6 QWVVGP
Reptiles
American chameleon (Anolis carolinensis) UP H9GD35 QWVVGP
Bearded dragon (Pogona vitticeps) GB XP_020666227 QWVVGP
Chinese softshell turtle (Pelodiscus sinensis) UP K7GGY5 QWVIGP
Chinese alligator (Alligator sinensis) UPA0A1U7RBY2 QWVVGP
Burmese python (Python bivittatus) GB XP_025031668 QWVVGP
Amphibians
African clawed frog (Xenopus laevis) UP Q7SYH2 QWVVGP
Western clawed frog (Xenopus tropicalis) GB XP_002937874 QWVVGP
High Himalaya frog (Nanorana parkerii) GB XP_018422589 QWMFGQ
Axolotl (Ambystoma mexicanum) ‡ QWVFGP
Bony fishes
Channel catfish (Silurus punctatus) UP W5UDH5 QWIVGP
Rainbow trout (Oncorhynchus mykiss) GB XP_021460414 QWVVGP
Atlantic salmon (Salmo salar) UPA0A1S3KKB8 QWVVGP
Turbot (Scophthalmus maximus) UPA0A221J5J5 QWVVGP
Three-spined stickleback (Gasterosteus aculeatus) UP G3NQ86 QWVVGP
Nile tilapia (Oreochromis niloticus) UP I3JY83 QWVVGP
Japanese killifish (Oryzias latipes) UP H2MAI0 QWVVWP
Zebrafish (Danio rerio) UPA5D6T5 QWMVGA
Coelacanth (Latimeria chalumnae) UP M3XK68 QWMVGA
Cartilaginous fishes
Elephant shark (Callorhincus milii) GB XP_007897454 QGMFFE
† With human fetuin-B. ‡ http://www.ambystoma.org/index.php?option=com_content&view=article&id=67:ambystoma-
get-contig&catid=40:codepages&Itemid=2&species=2&mcid=contig331328.
Point mutations affecting the trunk within full-length mouse
fetuin-B all had negative effects on inhibition. The P155A
mutant caused a decrease in theKi values of roughly one order
of magnitude for astacin and meprin  and two orders of
magnitude for ovastacin. For the D156A mutant, we measured
an approximate decrease of two orders of magnitude for
astacin and meprin  and four orders of magnitude for ovas-
tacin. The corresponding double mutant caused an even
greater loss towards ovastacin and meprin  (four orders of
magnitude) and astacin (two orders of magnitude) [Figs. 3(b)
and 3(c)]. Thus, similar to the mFBABA mutant, the double
mutant is merely a micromolar inhibitor [Fig. 3(c)] that is
insufficient to block ovastacin under physiological conditions.
Likewise, the C154S+C157S mutant led to a substantial decrease
in Ki. Finally, grafting the sequence of CY1 hairpin I onto CY2
(H1-swap mutant; QEDMGP instead of QWVSGP) also led
to substantially higher Ki values [Figs. 3(b) and 3(c)]. This
indicates that the conserved QXVXGP sequence motif of H1
is required for efficient inhibition of astacins.
Overall, the fact that the mutants and variants have
comparable effects on astacin, meprin  and ovastacin
supports the crayfish enzyme as a valid structural model for
the mammalian orthologs. The results confirm that the major
functional interactions between fetuin-B and astacin/ovastacin
are made by the CPDCP-trunk and hairpin I of domain CY2
and that any modification leads to a decrease in inhibitory
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Figure 3
In vitro validation of the inhibitory mechanism. (a) Activity (%) of astacin (at 1 nM concentration), meprin  (at 1 nM concentration) and ovastacin (at
5.6 nM) in the presence of fetuin-B variants at 300 nM (CPDC and CPRC) or 12.5 nM (other variants). Full astacin, meprin  and ovastacin activities
(100%) correspond to substrate-turnover rates of 35.4  5.7, 7.7  0.2 and 10.7  0.8 nM s1, respectively; w/o, without fetuin; hFB, human fetuin-B;
bFB, bovine fetuin-B; mFB, murine fetuin-B; mFBCY2, CY2 domain of mFB; mFBCTR, CTR domain of mFB; mFBC39S,C374S, double point mutant of
murine fetuin-B; CPDC and CPRC, cyclic peptides comprising the respective sequences. Experiments were performed in triplicate; error bars indicate
standard deviations. (b) Plot of fractional velocity (logarithmic scale) with different fetuin-B variants: mFB, murine fetuin-B; mFBABA, variant with CY1
and CTR from mouse fetuin-A and CY2 from mFB; mFBH1-swap, mutant replacing CY2 hairpin I with CY1 hairpin I; mFBP155A, mFBD156A,
mFBP155A,D156A and mFBC154S,C157S are point mutants of murine fetuin-B. Enzyme and substrate concentrations were 1.0 nM and 195 mM for astacin,
0.5 nM and 26 mM for meprin  and 0.7 nM and 26 mM for ovastacin, respectively. Error bars indicate standard deviations. (c)Ki values determined from
(b) using Morrison’s equation with the respective standard errors (SE).
power. Moreover, an overall scaffold encompassing
CY1+LNK+CY2 is indispensable to exert full inhibitory
potency.
3.5. Comparison with the inhibition mechanism of cysteine
peptidases by cystatins
The inhibitory mechanism of cysteine peptidases by
monomeric cystatins has been dubbed the ‘elephant-trunk
model’ (Turk & Bode, 1991) and is mainly exerted by the
N-terminal segment of the inhibitor (the ‘trunk’). This
segment precedes the first strand of the -sheet and occupies
the S1 and upstream nonprimed subsites of the cleft (Stubbs et
al., 1990; Turk & Bode, 1991). On the primed side, hairpin I
contains the conserved sequence QXVXG, which functions
similarly to hairpin I of fetuin-B with motif QWVXGP (see
above). Finally, hairpin II of cystatin provides a scaffold for
hairpin I and performs ancillary interactions with the enzyme
through the conserved PW motif. Overall, the inhibitory
mechanism of MPs by fetuin-B, in which the extended
N-terminal trunk is replaced by a compact CPDCP-trunk that
resembles a ‘raising trunk’ [inset in Fig. 2(d)], contains
elements of similarity to the hydrophobic tripartite wedge of
cystatins tackling cysteine peptidases. This suggests that gene
duplication and molecular evolution of cysteine-peptidase
targeting cystatins eventually led to inhibition of peptidases of
a different chemical class. We thus hereby propose the term
‘raised-elephant-trunk mechanism’ to describe the mode of
inhibition of astacins by fetuin-B [Fig. 2(d)].
3.6. Implications for inhibitory fetuins
The alignment of representative sequences of (potential)
mammalian fetuin-B orthologs revealed that they share the
same overall length (374–388 residues) and show high
sequence identity to the human form, which ranges from 98%
(gorilla) to 47% (opossum) (see Table 3). The orthologs
contain the sequence of the CPDCP-trunk and the length and
sequence of the QWVXGP motif (Table 3, Supplementary
Figs. S2 and S3), as well as a similar CTR. This suggests that
mammalian fetuin-B orthologs probably exhibit equivalent
structures and inhibit astacins via the proposed raised-
elephant-trunk mechanism, as has been confirmed to date for
the bovine, human and murine forms [Fig. 3(a)].
Outside mammals, carp fetuin efficiently inhibited
nephrosin (Tsai et al., 2004) and human meprin  and , but
not astacin (Hedrich et al., 2010). This fetuin occurs in two
isoforms, which have a CTR that is either shorter or longer
than that in mouse fetuin-B but is in both cases dispensable for
inhibition (Hedrich et al., 2010). Although somewhat more
distant in evolution than the mammalian orthologs (24%
sequence identity between the first 306 residues of mouse
fetuin-B and the entire short variant), carp fetuin also contains
the CPDCP-trunk to bind the catalytic zinc, but hairpin I has
one extra residue in the sequence: QWMFSGQ. This would
entail steric clashes with the primed side of the cleft of astacin,
but not of meprin  (PDB entry 1gwn; Arolas et al., 2012), the
cleft of which is deeper. This explains the distinct inhibitory
behavior towards these enzymes.
Other vertebrates (birds, reptiles, amphibians, bony fishes
and cartilaginous fishes) contain potential orthologs with both
the CPDCP-trunk and a putative hairpin I with a QWVXGP-
derived sequence (Table 3). They should thus indiscriminately
inhibit meprins, astacin and ovastacin. However, the CTRs
strongly deviate from mammalian sequences and range from
short tails to hundreds of residues. In particular, the Chinese
softshell turtle sequence only spans 264 residues and is
apparently a natural variant containing just CY1+LNK+CY2.
Moreover, no sequences were found within cyclostomes,
cephalochordates, urochordates, echinoderms or hemi-
chordates within deuterostomes. Thus, fetuin-B sequences are
absent from jawless fish and are restricted to jawed verte-
brates, for which the raised-elephant-trunk mechanism might
be valid.
3.7. Why fetuin-A is not an astacin inhibitor
To investigate the lack of inhibitory activity of fetuin-A
(Karmilin et al., 2019), we calculated a homology model for the
human form based on the coordinates of mouse fetuin-B (28%
sequence identity) and the experimentally determined disul-
fide pattern (Kellermann et al., 1989). According to this model,
the overall structure would be very similar to that of fetuin-B
and likewise would encompass CY1 (G22–S138; human fetuin
A residue numbers are shown in italics; see UniProt P02765),
LNK (A139–P150), CY2 (L151–Q251) and CTR (T252–V367)
domains. It would also include a potential CPDCP-trunk
(C146QDCP150), which would be solvent-exposed, as well as
the upstream major physiological trypsin cleavage site of
human fetuin-A (K143–K144; Kellermann et al., 1989).
Moreover, the segments equivalent to Y77–Q78 and H151TT153
of fetuin-B are sensitive to proteolysis in some fetuin-A
orthologs (Olivier et al., 2000, Kellermann et al., 1989). These
segments map to CY1 hairpin I and helix 3, respectively,
which are likewise surface-located.
The second position of the CPDCP-trunk is occupied by a
glutamine in human fetuin-A (Q147), which could potentially
interfere with active-site residues of the MP and thus impair
inhibition. In contrast to the fetuin-B orthologs, the trunk
motif shows variability across mammalian fetuin-A orthologs:
CPRCP in mouse, CPQCP in cat, CPNCP in pig etc. In the
bovine and rabbit orthologs the sequence even corresponds to
that of fetuin-B. Collectively, these findings support the above
results in vitro that the ‘warhead’ is a necessary but not
sufficient element of inhibition. Indeed, the main reason for
the lack of inhibition of human fetuin-A is that CY2 hairpin I
is one residue shorter, shows a disparate sequence (V191PL-
PLPP195 instead of QWVXGP) and probably shows a
distorted geometry owing to the two extra prolines [Fig. 2(e)].
In addition, the CY2 hairpin II would be nine residues shorter
(K237–G240 instead of S244–E256). Taken together, these
differences in crucial and ancillary structural elements of the
raised-elephant-trunk model would explain the lack of inhi-
bitory competence of fetuin-A.
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4. Conclusion
Discovered over seven decades ago in mammalian serum,
the fetuins are a widespread family of vertebrate proteins.
Fetuin-B is the only endogenous, specific, potent inhibitor of
non-BMP-1-like astacin MPs through a conserved aspartate
within a CPDCP-trunk that blocks the active-site cleft. This is
reminiscent of the aspartate-switch mechanism that is
responsible for latency in astacin zymogens, in which an
aspartate likewise blocks the catalytic zinc (Guevara et al.,
2010; Arolas et al., 2012).
CY1, LNK and CY2 are required for the inhibitory function
of fetuin-B, but not the CTR, which is flexible and depleted
of regular secondary structure, i.e. it can potentially adopt
several conformations. By lining the exposed surface of CY1
and being covalently linked to it, the CTR provides fetuins
with an adaptable surface to potentially bind many proteins
and exert disparate signaling functions (Dunker et al., 2000),
which may be independent of inhibition of proteolysis.
Finally, we found sequences of proven and potential fetuin-
B orthologs encompassing the CPDCP and QWVXGP motifs
throughout jawed vertebrates down the tree of life as far as
cartilaginous fish. In turn, astacins are present across animals,
including lower vertebrates and invertebrates such as nema-
todes, mostly as several paralogs per organism (Gomis-Ru¨th,
Trillo-Muyo et al., 2012). This phylogenetic coexistence
suggests that the raised-elephant-trunk mechanism described
here may represent a general mechanism of endogenous
regulation of astacin MPs through dedicated and potent
protein inhibitors.
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